Books, Posters, Presentations from 2018
Current and Emerging Treatments for Psoriatic Arthritis, Philip Mease
Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison., Philip Mease, Ernest Choy, Peter Nash, Chrysostomos Kalyvas, Matthias Hunger, Luminita Pricop, Kunal K Gandhi, Steffen M Jugl, and Howard Thom
Considerations for the definition of remission criteria in psoriatic arthritis., Philip Mease and Laura C Coates
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial., Philip Mease, Laura C Coates, Philip S Helliwell, Mykola Stanislavchuk, Anna Rychlewska-Hanczewska, Anna Dudek, Walid Abi-Saab, Chantal Tasset, Luc Meuleners, Pille Harrison, Robin Besuyen, Annegret Van der Aa, Neelufar Mozaffarian, Joy M Greer, Rebecca Kunder, Filip Van den Bosch, and Dafna D Gladman
Phase 2 Study of ABT-122, a TNF- and IL-17A-Targeted Dual Variable Domain Immunoglobulin, in Psoriatic Arthritis With Inadequate Methotrexate Response., Philip Mease, Mark C Genovese, Michael E Weinblatt, Paul M Peloso, Kun Chen, Ahmed A Othman, Yihan Li, Heikki T Mansikka, Amit Khatri, Neil Wishart, and John Liu
Tofacitinib for Psoriatic Arthritis., Philip Mease and Dafna Gladman
Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)., Philip Mease, Dafna D Gladman, Ahmed S Samad, Laura C Coates, Lyrica X H Liu, Girish A Aras, David H Collier, and James B Chung
CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study., Philip J Mease, Slawomir Jeka, Juan Jose Jaller, Tasanee Kitumnuaypong, Worawit Louthrenoo, Herman Mann, Galina Matsievskaia, Enrique R Soriano, Bin Jia, Caihong Wang, Jing Nie, and Elizabeth Hsia
Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial., Philip J Mease, Arthur Kavanaugh, Andreas Reimold, Hasan Tahir, Jürgen Rech, Stephen Hall, Piet Geusens, Pascale Pellet, Evie Maria Delicha, Shephard Mpofu, and Luminita Pricop
Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry., Philip J Mease, Jacqueline B Palmer, Mei Liu, Arthur Kavanaugh, Renganayaki Pandurengan, Christopher T Ritchlin, Chitra Karki, and Jeffrey D Greenberg
Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry., Philip J Mease, Désirée van der Heijde, Chitra Karki, Mei Liu, Yujin Park, and Jeffrey D Greenberg
Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Chitra Karki, Mei Liu, Arthur Kavanaugh, Christopher T Ritchlin, Doquyen Hoa Huynh, Jacqueline B Palmer, and Jeffrey D Greenberg
Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial., Philip Mease, A Kavanaugh, and A Reimold
Axial Spondyloarthritis, Philip Mease and Muhammad Asim Khan
Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical Trials., Philip Mease, Euthalia Roussou, Gerd-Rüdiger Burmester, Philippe Goupille, Alice Gottlieb, Susan R Moriarty, Olivier Benichou, David H Adams, Wen Xu, and Peter Nash
Functional impairment measurement in psoriatic arthritis: Importance and challenges., Philip Mease, Vibeke Strand, and Dafna Gladman
Characterization of Patients With Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in the US-Based Corrona Registry., Philip Mease, Désirée van der Heijde, Chitra Karki, Jacqueline B Palmer, Mei Liu, Renganayaki Pandurengan, Yujin Park, and Jeffrey D Greenberg
Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study., Philip Mease, Désirée van der Heijde, Robert Landewé, Shephard Mpofu, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Karin Meiser, Aimee Readie, Luminita Pricop, and Ken Abrams
The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis., Philippe Mertz, Alexandre Belot, Ricard Cervera, Tyng Yu Chuah, Lorenzo Dagna, Laura Damian, Debashish Danda, David D'cruz, Gerard Espinosa, Camille Frances, David Jayne, Kong Kok Ooi, Eugene J Kucharz, Robert Lebovics, Isabelle Marie, Guillaume Moulis, Stanford Peng, Aman Sharma, Noboru Suzuki, Toshio Tanaka, Ronald Van Vollenhoven, Jean Sibilia, Jacques Eric Gottenberg, François Chasset, and Laurent Arnaud
Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison., Peter Nash, Iain B McInnes, Philip Mease, Howard Thom, Matthias Hunger, Andreas Karabis, Kunal Gandhi, Shephard Mpofu, and Steffen M Jugl
Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison., Peter Nash, Iain B McInnes, Philip Mease, Howard Thom, Matthias Hunger, Andreas Karabis, Kunal Gandhi, Shephard Mpofu, and Steffen M Jugl
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)., Peter Nash, Philip Mease, Iain B McInnes, Proton Rahman, Christopher T Ritchlin, Ricardo Blanco, Eva Dokoupilova, Mats Andersson, Radhika Kajekar, Shephard Mpofu, and Luminita Pricop
PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials., Ana-Maria Orbai, Richard Holland, Ying Ying Leung, William Tillett, Niti Goel, Robin Christensen, Neil McHugh, Laure Gossec, Maarten de Wit, Pil Højgaard, Laura C Coates, Philip Mease, Julie Birt, Lara Fallon, Oliver FitzGerald, Alexis Ogdie, Beverly Shea, Vibeke Strand, Kristina Callis Duffin, Peter Tugwell, Dorcas Beaton, and Dafna D Gladman
The International Consortium for Health Outcome Measurement (ICHOM)Set of Outcomes that Matter to People Living with Inflammatory Arthritis Consensus from an international Working Group., Martijn A H Oude Voshaar, Zofia Das Gupta, Johannes W J Bijlsma, Annelies Boonen, Jeffrey Chau, Delphine S Courvoisier, Jeffrey R Curtis, Benjamin Ellis, Sofia Ernestam, Laure Gossec, Christine Hale, Jennifer Hornjeff, Katy Y Y Leung, Merav Lidar, Phillip Mease, Kaleb Michaud, Girish M Mody, Mwidimi Ndosi, Christina H Opava, Geraldo R C Pinheiro, Matthew Salt, Enrique R Soriano, William J Taylor, Maria J H Voshaar, Angelique E A M Weel, Maarten de Wit, Nico Wulffraat, Mart A F J van de Laar, and Harald E Vonkeman
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force., Josef S Smolen, Monika Schöls, Jürgen Braun, Maxime Dougados, Oliver FitzGerald, Dafna D Gladman, Arthur Kavanaugh, Robert Landewé, Philip Mease, Joachim Sieper, Tanja Stamm, Maarten de Wit, Daniel Aletaha, Xenofon Baraliakos, Neil Betteridge, Filip van den Bosch, Laura C Coates, Paul Emery, Lianne S Gensler, Laure Gossec, Philip Helliwell, Merryn Jongkees, Tore K Kvien, Robert D Inman, Iain B McInnes, Mara Maccarone, Pedro M Machado, Anna Molto, Alexis Ogdie, Denis Poddubnyy, Christopher Ritchlin, Martin Rudwaleit, Adrian Tanew, Bing Thio, Douglas Veale, Kurt de Vlam, and Désirée van der Heijde
Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2., Filip Van den Bosch, Philip Mease, Joachim Sieper, Dominique L Baeten, Yinglin Xia, Su Chen, Aileen L Pangan, and In-Ho Song
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial., Désirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, Philip Mease, Atul Deodhar, Walter P Maksymowych, Filip Van den Bosch, Joachim Sieper, Tetsuya Tomita, Robert Landewé, Fangyi Zhao, Eswar Krishnan, David H Adams, Beth Pangallo, and Hilde Carlier
4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis., Désirée van der Heijde, Atul Deodhar, Oliver FitzGerald, Roy Fleischmann, Dafna Gladman, Alice B Gottlieb, Bengt Hoepken, Lars Bauer, Oscar Irvin-Sellers, Majed Khraishi, Luke Peterson, Anthony Turkiewicz, Jürgen Wollenhaupt, and Philip Mease
Correction: 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis., Désirée van der Heijde, Atul Deodhar, Oliver FitzGerald, Roy Fleischmann, Dafna Gladman, Alice B Gottlieb, Bengt Hoepken, Lars Bauer, Oscar Irvin-Sellers, Majed Khraishi, Luke Peterson, Anthony Turkiewicz, Jürgen Wollenhaupt, and Philip Mease
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)., Désirée van der Heijde, Dafna D Gladman, Mitsumasa Kishimoto, Masato Okada, Suchitrita S Rathmann, Susan R Moriarty, Catherine L Shuler, Hilde Carlier, Olivier Benichou, and Philip J Mease
Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial., J A Walsh, A B Gottlieb, B Hoepken, T Nurminen, and P J Mease
Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial., J A Walsh, A B Gottlieb, B Hoepken, T Nurminen, and P J Mease
Percutaneous Ultrasonic Tenotomy for Refractory Common Extensor Tendinopathy After Failed Open Surgical Release: A Report of Two Cases., Reed C Williams and Adam M Pourcho
The unmet need in rheumatology: Reports from the targeted therapies meeting 2017., Kevin L Winthrop, Vibeke Strand, Désirée van der Heijde, Philip Mease, Mary Crow, Michael Weinblatt, Joan Bathon, Gerd R Burmester, Maxime Dougados, Johnathan Kay, Xavier Mariette, Ronald Van Vollenhoven, Joachim Sieper, Fritz Melchers, Ferdinand C Breedfeld, Joachim Kalden, Josef S Smolen, and Daniel E Furst
Submissions from 2017
The feasibility of implementing the ICHOM Standard Set for Hip and Knee Osteoarthritis: a mixed-methods evaluation in public and private hospital settings., Ilana N Ackerman, Bernarda Cavka, Jacob Lippa, and Andrew Bucknill
International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting., Laura C Coates, Vinod Chandran, Alexis Ogdie, Denis O'Sullivan, Mel Brooke, Ingrid Steinkoenig, Philip Mease, Christopher T Ritchlin, and Arthur Kavanaugh
Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1., Laura C Coates, Mitsumasa Kishimoto, Alice Gottlieb, Catherine L Shuler, Chen-Yen Lin, Chin Hyok Lee, and Philip Mease
GRAPPA 2016 Project Report., Philip S Helliwell, Oliver FitzGerald, Laura C Coates, Kristina Callis Duffin, and Philip Mease
Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis., D H Huynh, T A Boyd, C J Etzel, V Cox, J Kremer, P Mease, and A Kavanaugh
Proceedings of the GRAPPA 2016 Retreat., Deepak R Jadon, Dafna D Gladman, Philip Mease, Oliver FitzGerald, Vinod Chandran, Niti Goel, Cheryl F Rosen, Walter P Maksymowych, Christopher T Ritchlin, Alexis Ogdie, Laura C Coates, Alberto Cauli, Enrique R Soriano, M Elaine Husni, Willemina Campbell, Valderilio F Azevedo, Kristina Callis Duffin, April W Armstrong, Alice B Gottlieb, Arthur Kavanaugh, Amit Garg, and Philip S Helliwell
Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study., Lars Erik Kristensen, Tanja S Jørgensen, Robin Christensen, Henrik Gudbergsen, Lene Dreyer, Christine Ballegaard, Lennart T H Jacobsson, Vibeke Strand, Philip Mease, and Jakob Kjellberg
Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study., Iain B McInnes, Philip Mease, Christopher T Ritchlin, Proton Rahman, Alice B Gottlieb, Bruce Kirkham, Radhika Kajekar, Eumorphia-Maria Delicha, Luminita Pricop, and Shephard Mpofu
New pathways of treatment for psoriatic arthritis., Philip Mease
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis., Philip Mease, Alice B Gottlieb, Désirée van der Heijde, Oliver FitzGerald, Alyssa Johnsen, Marleen Nys, Subhashis Banerjee, and Dafna D Gladman
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis., Philip Mease, Stephen Hall, Oliver FitzGerald, Désirée van der Heijde, Joseph F Merola, Francisco Avila-Zapata, Dorota Cieślak, Daniela Graham, Cunshan Wang, Sujatha Menon, Thijs Hendrikx, and Keith S Kanik
Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Chitra Karki, Jacqueline B Palmer, Carol J Etzel, Arthur Kavanaugh, Christopher T Ritchlin, Wendi Malley, Vivian Herrera, Melody Tran, and Jeffrey D Greenberg
Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial., Philip Mease, Arthur Kavanaugh, Laura C Coates, Iain B McInnes, Maja Hojnik, Ying Zhang, Jaclyn K Anderson, Alexander P Dorr, and Dafna D Gladman
Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry., Philip Mease, Tamara Lesperance, Mei Liu, David H Collier, Marc Mason, Sabrina Deveikis, and Neil A Accortt
Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab., Philip Mease, Filip Van den Bosch, Joachim Sieper, Yinglin Xia, Aileen L Pangan, and In-Ho Song
Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group., Alexis Ogdie, Maarten de Wit, Kristina Callis Duffin, Willemina Campbell, Jeffrey Chau, Laura C Coates, Lihi Eder, Musaab Elmamoun, Oliver FitzGerald, Dafna D Gladman, Niti Goel, Jana James, Umut Kalyoncu, John Latella, Chris Lindsay, Philip Mease, Denis O'Sullivan, Ingrid Steinkoenig, Vibeke Strand, William Tillett, and Ana-Maria Orbai
Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016., Ana-Maria Orbai, Maarten de Wit, Philip Mease, Kristina Callis Duffin, Musaab Elmamoun, William Tillett, Willemina Campbell, Oliver FitzGerald, Dafna D Gladman, Niti Goel, Laure Gossec, Pil Hoejgaard, Ying Ying Leung, Chris Lindsay, Vibeke Strand, Désirée M van der Heijde, Bev Shea, Robin Christensen, Laura Coates, Lihi Eder, Neil McHugh, Umut Kalyoncu, Ingrid Steinkoenig, and Alexis Ogdie
Total Ankle Replacement with Severe Valgus Deformity: Technique and Surgical Strategy., John M Schuberth, Jeff C Christensen, and Chad L Seidenstricker
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA., Désirée van der Heijde, Maxime Dougados, Robert Landewé, Joachim Sieper, Walter P Maksymowych, Martin Rudwaleit, Filip Van den Bosch, Jürgen Braun, Philip Mease, Alan J Kivitz, Jessica Walsh, Owen Davies, Lars Bauer, Bengt Hoepken, Luke Peterson, and Atul Deodhar
